F Bertucci,P Finetti,L Mescam et al.
F Bertucci et al.
Background: Soft tissue sarcomas (STSs) are aggressive and heterogeneous tumors with few efficient systemic therapies. Antibody-drug conjugates (ADCs) represent an emerging therapeutic option in oncology. Their efficacy i...
NALIRIFOX in the treatment of metastatic pancreatic ductal adenocarcinoma: an exploratory analysis of real-world data [0.03%]
NALIRIFOX在转移性胰腺导管腺癌治疗中的疗效:真实世界数据的探索性分析
A Reichinger,A Friedrich,T Lentner et al.
A Reichinger et al.
Background: NALIRIFOX, a triplet chemotherapy regimen combining nanoliposomal irinotecan, 5-fluorouracil/leucovorin, and oxaliplatin, demonstrated superior survival outcomes versus gemcitabine plus nab-paclitaxel in the N...
Cyclin-dependent kinase 4/6 inhibitors beyond progression in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis (REIGNITE study) [0.03%]
激素受体阳性、HER2阴性晚期乳腺癌患者在接受细胞周期蛋白依赖性激酶4/6抑制剂治疗进展后的疗效:系统评价和meta分析(REIGNITE研究)
L F C de Almeida,L F Leite,V O C Filho et al.
L F C de Almeida et al.
Background: Adding cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) to endocrine therapy (ET) is considered the first-line treatment of advanced HR-positive/HER2-negative breast cancer. However, with the recent approval o...
Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer [0.03%]
Trodelvy治疗转移性乳腺癌患者的生存结局和DNADX液体活检的指导价值
S Morganti,R J Kusmick,M E Hughes et al.
S Morganti et al.
Background: Sacituzumab govitecan (SG) is an anti-trop2 antibody-drug conjugate (ADC) approved for human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). However, data on effectiveness of...
Minimum standards of specialist adolescent and young adult (AYA) cancer care units: recommendations and implementation roadmap [0.03%]
青少年及年輕成人患者癌癥護理單位的最低標準:建議和落實路線圖
U Košir,A Totovina,D Stark et al.
U Košir et al.
In 2022, according to the Global Cancer Observatory, >115 000 adolescents and young adults (AYAs; aged 15-39 years) were diagnosed with cancer across Europe. Despite their unique biological and psychosocial needs, AYAs face disparity of acc...
Artificial intelligence defines spatial patterns of tumor-infiltrating lymphocytes highly associated with outcome - a pan-GI cancer study [0.03%]
人工智能定义胃肠道肿瘤浸润淋巴细胞的空间分布模式并与预后高度相关
C Chen,H A Mejbel,T Pathak et al.
C Chen et al.
Background: Gastrointestinal (GI) cancers (including esophagus, stomach, colon, rectum, pancreas and liver) account for more than one-quarter of all cancer diagnoses and 35% of cancer-related fatalities worldwide. Quantif...
Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer [0.03%]
ZOLBEtüximab联合化疗引起的CLDN18.2阳性胃癌患者的早期胃炎的特征研究
K Yamamoto,Y Owaki,I Nakayama et al.
K Yamamoto et al.
Background: Zolbetuximab, a monoclonal antibody targeting claudin 18.2 (CLDN18.2), plus chemotherapy has become a standard treatment for CLDN18.2-positive advanced gastric cancer and is frequently associated with early-on...
Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial [0.03%]
帕博利珠单抗联合曲妥珠单抗和化疗治疗HER2阳性晚期胃癌:关键-note-811随机试验的健康相关生活质量分析
Y Y Janjigian,A Kawazoe,J Xu et al.
Y Y Janjigian et al.
Background: In the primary analysis of the randomized phase III KEYNOTE-811 trial (NCT03615326), pembrolizumab plus trastuzumab and chemotherapy improved progression-free survival and overall survival versus placebo plus ...
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial [0.03%]
抗PD-1治疗在PD1高表达的mRNA肿瘤中的疗效:II期SOLT I-1904 ACROPOLI试验第1部分和第2部分的结果
E Seguí,F Brasó-Maristany,T Pascual et al.
E Seguí et al.
Background: Immune checkpoint inhibitors (ICIs) have transformed the treatment of solid tumors, yet responses vary across cancer types, highlighting the need for reliable pan-cancer biomarkers. Prior retrospective studies...